Skip to main content
MJFF in the News

Press Releases

Browse current and past press releases from The Michael J. Fox Foundation.

  • Default content image

    Michael J. Fox Honored with Elevate Prize Catalyst Award for His Dedication and Leadership to Parkinson’s Research and Advocacy

    NEW YORK (September 20, 2023) — The Michael J. Fox Foundation for Parkinson’s Research (MJFF) congratulates founder Michael J. Fox as the recipient of the 2023 Elevate Prize Catalyst Award conferred…

  • Default content image

    Global Consortium Identifies Novel Parkinson’s Genetic Risk Factor in African Populations

    Cross-cohort analysis found novel variant in GBA1 gene associated with higher risk of Parkinson’s in people of African ancestry Finding is from Nigerian and U.S. cohorts contributing to the Global…

  • Default content image

    Michael J. Fox Foundation Announces Significant Breakthrough in Search for Parkinson's Biomarker

    New paper in The Lancet Neurology confirms that a key Parkinson’s pathology can now be identified by examining spinal fluid from living patients Test validated in the gold-standard Parkinson’s…

  • Default content image

    The Michael J. Fox Foundation Partners with Canadian Parkinson’s Community to Expand International Landmark Parkinson's Study

    The Michael J. Fox Foundation’s landmark Parkinson’s Progression Markers Initiative (PPMI) study expands recruitment to Canada to help speed cures and disease prevention Canadians recently diagnosed…

  • Default content image

    Michael J. Fox Foundation for Parkinson’s Research Announces Promising Results, Next Steps for “Ken Griffin Alpha-synuclein Imaging Competition”

    Competition funded by Citadel founder and CEO Ken Griffin spurred a scientific race to develop an imaging tracer to visualize the key protein alpha-synuclein in the living brains of people with…

  • Default content image

    Early Trial Results Give Hope for a New Potential Dyskinesia Treatment for People with Parkinson’s

    Positive results suggest NLX-112 is safe and efficacious for people with Parkinson’s with levodopa-induced dyskinesias These challenging involuntary movements have been identified as a priority for…

  • Default content image

    Study of Parkinson’s Disease Genetics in Black and African American Populations Expands with Two Additional Sites

    Black and African American Connections to Parkinson’s Disease (BLAAC PD) study builds to six sites with the inclusion of Louisiana State University and University of Florida   Collaborative…

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.